Germany Establishing a genuine European investment promotion platform is crucial Achim Hartig, Director of Foreign Direct Investment at Germany Trade & Invest (GTAI) and Chair of the OECD Network of Investment Promotion Agencies, discusses Germany’s evolving investment priorities, spanning healthcare, energy, digital technologies and mobility. He highlights the country’s strengths in…
Germany Dr Gertrud Demmler of SBK, one of Germany’s largest statutory health insurance funds, describe the EUR 18 billion funding gap facing the country’s health system, what the July 2026 GKV Contribution Rate Stabilisation Act does and doesn’t fix, why consolidation among health insurance funds is set to continue, and the…
USA Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this remains a complex and challenging field, leading neuroscience biotechs – three of which are profiled below – to develop very…
Europe Europe’s place in the global biotechnology race is entering a decisive phase. Scientific excellence and industrial depth remain powerful advantages, yet intensifying competition from the United States and China is exposing the need for faster execution, stronger capital markets, and a more coherent single market. Claire Skentelbery outlines why biotechnology…
Germany Money follows the science, and the science here in Bavaria is excellent Ralf Huss, Chief Executive of BioM, discusses how Bavaria has built one of Europe’s leading biotechnology ecosystems by connecting researchers, entrepreneurs, investors and global pharmaceutical companies. He highlights BioM‘s role in supporting more than 500 companies, accelerating start-ups…
Germany Germany and Europe have every reason to remain optimistic, provided we build on the strengths we already have As Europe seeks to strengthen its pharmaceutical resilience and Germany redefines its healthcare and industrial priorities, the decisions taken today will shape the sector’s competitiveness for decades to come. Dr Kai Joachimsen,…
Korea Korea has something that very few countries can claim: high-quality healthcare data at genuine population scale JK Lee, Vice President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), outlines Korea’s transition from a generics-driven industry to a global innovation hub. He highlights the government’s strategic support, a growing pipeline…
Korea If you concentrate on shared goals, collaboration and a unified voice follow naturally. Youngshin Lee, CEO of KRPIA, has built a career spanning more than three decades across pharmaceutical R&D, industry, and policy, advocating for collaboration between regulators, industry, and patients. Under her leadership, KRPIA has become a key voice…
Korea As the world around us changes, we need to change with it Marie Antonia von Schönburg has been President and Chief Executive of the Korean-German Chamber of Commerce and Industry in Seoul for 16 months. With 26 years of experience across the global network of German Chambers abroad,…
Germany Germany remains one of Europe’s most important pharmaceutical markets, combining scientific excellence, strong clinical research capabilities, and early access to innovation. Yet as breakthrough therapies become more sophisticated and global competition for investment intensifies, maintaining that position will require more than scientific strength alone. Urs Voegeli, Managing Director of Johnson…
Taiwan Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through the state-backed TSMC (Taiwan Semiconductor Manufacturing Company), the island functions as the world’s foundry, manufacturing the advanced chips designed by…
Taiwan Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At the foundation of that achievement sits a network of domestic generic and OTC manufacturers, several of them family-owned businesses now…
See our Cookie Privacy Policy Here
